Bill > S1227

This bill, the Prescription Pricing for the People Act of 2019, requires the Federal Trade Commission (FTC) to study the role of pharmaceutical supply chain intermediaries, such as pharmacy benefit managers (PBMs), and their impact on prescription drug costs. The FTC must report to Congress on whether PBMs charge payers (like Medicare and Medicaid) higher prices than they reimburse non-affiliated pharmacies, steer patients to PBM-owned pharmacies, use proprietary data to benefit their own pharmacies, and use formulary designs to favor higher-cost drugs. The report must also examine the state of competition in the healthcare supply chain, how companies and payers assess the costs and benefits of contracting with intermediaries, and any legal or regulatory obstacles the FTC faces in enforcing antitrust and consumer protection laws in this market. The FTC must provide policy and legislative recommendations to improve transparency, prevent anticompetitive behavior, and ensure consumers benefit from any cost savings or efficiencies resulting from industry consolidation.

Justice

https://www.congress.gov/bill/116th-congress/senate-bill/1227/all-info